Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT06376916

Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

Led by Wake Forest University Health Sciences · Updated on 2025-10-28

153

Participants Needed

1

Research Sites

112 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.

CONDITIONS

Official Title

Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age > 18 years or older
  • Able to provide informed consent
  • Primary diagnosis of atrial fibrillation or atrial flutter with rapid ventricular response (heart rate ≥ 120 bpm)
  • Currently treated with diltiazem as a rate control agent
  • Able to speak and understand English
Not Eligible

You will not qualify if you...

  • Hemodynamically unstable patients (systolic blood pressure < 90, mean arterial pressure < 65)
  • Impaired consciousness
  • End stage renal disease requiring hemodialysis or peritoneal dialysis
  • Acute heart failure exacerbation diagnosed clinically or with imaging
  • AFF RVR suspected to be a compensatory response to another diagnosis
  • Heart rhythms other than atrial fibrillation, such as sick sinus syndrome or wide-complex ventricular response
  • Acute myocardial infarction
  • Pregnancy (positive urine human chorionic gonadotropin test)
  • Contraindications to magnesium sulfate (including myasthenia gravis)
  • Allergy or sensitivity to any study drugs
  • Previously enrolled in this trial during a different encounter
  • Withdrawal from the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Advocate Christ Medical Center Emergency Department (ACMC ED)

Oak Lawn, Illinois, United States, 60453

Actively Recruiting

Loading map...

Research Team

M

Marc McDowell, PharmD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here